Erasca (ERAS) has had the highest return since January 1, 2026 by a mid-cap US stock, returning 339.6%.
| ASSET | % RETURN |
|---|---|
Erasca (ERAS) | 339.62% |
AXT (AXTI) | 286.31% |
Immunitybio (IBRX) | 261.39% |
Aehr Test Systems (AEHR) | 240.91% |
Ultra Clean (UCTT) | 194.41% |
Enliven Therapeutics (ELVN) | 182.77% |
Babcock & Wilcox Enterprises (BW) | 180.62% |
Tango Therapeutics (TNGX) | 143.62% |
Fastly, Inc Class A Common Stock (FSLY) | 135.91% |
Almonty Industries Inc Common Shares (ALM) | 134.85% |
Day One Biopharmaceuticals (DAWN) | 131.32% |
Alumis (ALMS) | 130.5% |
Viavi Solutions (VIAV) | 129.81% |
FormFactor (FORM) | 121.64% |
Dianthus Therapeutics (DNTH) | 118.92% |
Amprius Technologies (AMPX) | 117.63% |
Powell Industries (POWL) | 112.13% |
Veradermics (MANE) | 109.88% |
Aura Minerals Inc Common Shares (AUGO) | 104.9% |
Oruka Therapeutics (ORKA) | 102.51% |
Iridium Communications (IRDM) | 102.33% |
Sasol (SSL) | 99.69% |
Valaris (VAL) | 96.18% |
Chemours (CC) | 93.87% |
Spyre Therapeutics (SYRE) | 93.13% |
Mid-cap stocks are treated as having a market cap between $2B and $10B.
